Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.

Abstract:

:The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprofloxacin. Ten patients with hematologic malignancies who had < or = 108 granulocytes/mm3 after cytoreductive therapy and were afebrile for at least five days had intravenous antibiotics discontinued and were placed on oral ciprofloxacin. Eight patients were able to be discharged from the hospital and seven were treated without the need for reinstitution of intravenous therapy. Of the three failures, one developed fever with a new bloodstream infection and two developed fever with relapse of leukemia. Patients remained on ciprofloxacin an average of 14.5 days (range 4 to 35 days). Aggregate cost savings for the 10 patients from this approach were estimated to be $11,400 for antibiotics and $88,800 for hospitalization. If corroborated in larger, randomized studies, the use of "stepdown monotherapy" may be a cost effective approach to the management of the stable neutropenic patient.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Horowitz HW,Holmgren D,Seiter K

doi

10.3109/10428199609054816

subject

Has Abstract

pub_date

1996-09-01 00:00:00

pages

159-63

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

23

pub_type

临床试验,杂志文章
  • P27 in cell cycle control and cancer.

    abstract::In order to survive, cells need tight control of cell cycle progression. The control mechanisms are often lost in human cancer cells. The cell cycle is driven forward by cyclin-dependent kinases (CDKs). The CDK inhibitors (CKIs) are important regulators of the CDKs. As the name implies, CKIs were initially shown to ne...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009053535

    authors: Møller MB

    更新日期:2000-09-01 00:00:00

  • Chemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia.

    abstract::Long-term survivors of childhood leukemia are at risk for neurocognitive impairment, although the neurophysiological basis is not well understood. The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemothe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.717080

    authors: Krull KR,Hockenberry MJ,Miketova P,Carey M,Moore IM

    更新日期:2013-03-01 00:00:00

  • Clinical significance of detecting p53 protein in Burkitt lymphoma and B-cell acute lymphoblastic leukemia using immunocytochemistry.

    abstract::P53 protein expression in malignant cells of five patients with Burkitt lymphoma (BL) and from two patients with B-cell acute lymphoblastic leukemia (B-ALL) was examined with anti p53 protein monoclonal antibodies PAb1801, PAb240 and p53-D07 using an immunocytochemical technique. Four of the seven patients were positi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809058368

    authors: Nagai J,Kigasawa H,Koga N,Katoh A,Nishihira H,Nagao T

    更新日期:1998-02-01 00:00:00

  • Targeting oncoproteins for degradation by small molecules in myeloid leukemia.

    abstract::Oncoproteins play a vital role in the pathogenesis of myeloid leukemia. Most targeted therapies for myeloid leukemia are small molecules or monoclonal antibodies that inhibit the activity of the oncoproteins. However, leukemia cells often develop resistance to these drugs through overexpression of the target protein a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1403600

    authors: Lei H,Wang W,Wu Y

    更新日期:2018-10-01 00:00:00

  • Induction of differentiation of myeloid leukemic cells by busulphan: in vivo and in vitro observations.

    abstract::Treatment of a 74 year old patient with chronic myelogenous leukemia (CML) with busulphan resulted in an abrupt and pronounced decrease of the white blood cell (WBC) count with restoration of normal peripheral blood cell morphology and regression of splenomegaly. The Philadelphia positive (Ph+) clone was however still...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309087006

    authors: Michaeli J,Fibach E,Rachmilewitz EA

    更新日期:1993-10-01 00:00:00

  • Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies.

    abstract::SV40 DNA sequences have been detected in non-Hodgkin's lymphoma patients. A link between SV40 and NHL is biologically plausible since SV40 causes hematological malignancies in laboratory rodents. We investigated 266 Egyptian cases of hematological malignancies (158 NHL, 54 HD, 26 ALL, 13 AML, 8 CLL, 7 CML) and 34 subj...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701534408

    authors: Zekri AR,Mohamed W,Bahnassy A,Refat L,Khaled M,Shalaby S,Hafez M

    更新日期:2007-09-01 00:00:00

  • Novel agents versus chemotherapy as frontline treatment of CLL.

    abstract::Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1280606

    authors: Piggin A,Bayly E,Tam CS

    更新日期:2017-06-01 00:00:00

  • Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.

    abstract::The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509051698

    authors: Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

    更新日期:1995-03-01 00:00:00

  • Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique.

    abstract::Survival rates for Hodgkin lymphoma and non-Hodgkin lymphoma have improved in recent years. However, these improvements are associated with various late effects, which can compromise health-related quality of life (HRQoL). Improving HRQoL is a significant goal in oncology, and increasingly one of the primary outcomes ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428191003587263

    authors: Arden-Close E,Pacey A,Eiser C

    更新日期:2010-04-01 00:00:00

  • Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia.

    abstract::Bullous pyoderma gangrenosum begins as a bulla, nodule or nonulcerated erythematous plaque that blisters or ulcerates to form a superficial ulcer surrounded by a hemorrhagic, bullous border, which is surrounded by a blue-gray halo. Bullous pyoderma gangrenosum is most commonly associated with hematologic malignancies,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500254299

    authors: Fox LP,Geyer AS,Husain S,Grossman ME

    更新日期:2006-01-01 00:00:00

  • Gaucher disease and multiple myeloma.

    abstract::Gaucher disease (GD) is the most frequent lysosomal storage disease and corresponds to an inherited deficiency of glucocerebrosidase. Due to excessive accumulation of glucocerebroside in bone marrow, both cytopenia and bone lesions may occur. The incidence of malignant disorders has been evoked in non-neuronopathic ty...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190600565453

    authors: Costello R,O'Callaghan T,Sébahoun G

    更新日期:2006-07-01 00:00:00

  • Psychosocial life achievements in adults even if they received prophylactic cranial irradiation for acute lymphoblastic leukemia during childhood.

    abstract::The aim of this study was to assess life goal achievements in long-term survivors (LTS) receiving cranial radiotherapy (CRT) as central nervous system (CNS) prophylaxis for acute lymphoblastic leukemia (ALL) during childhood, compared to healthy individuals. Participants in this study were 141 LTS treated in our cente...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.710903

    authors: Pillon M,Tridello G,Boaro MP,Messina C,Putti MC,Varotto S,Petris MG,Scrimin S,Zanesco L,Rosolen A,Basso G

    更新日期:2013-02-01 00:00:00

  • Growth control mechanisms in multiple myeloma.

    abstract::Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809050906

    authors: Hawley RG,Berger LC

    更新日期:1998-05-01 00:00:00

  • Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

    abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.627480

    authors: Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

    更新日期:2012-05-01 00:00:00

  • Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes.

    abstract::Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematologi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1028053

    authors: Sánchez-Castro J,Marco-Betés V,Gómez-Arbonés X,García-Cerecedo T,López R,Talavera E,Fernández-Ruiz S,Ademà V,Marugan I,Luño E,Sanzo C,Vallespí T,Arenillas L,Marco Buades J,Batlle A,Buño I,Martín Ramos ML,Blázquez Rios B

    更新日期:2015-01-01 00:00:00

  • Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma.

    abstract::Morbidity, mortality and discomfort related to gastrectomy has led some investigators to treat patients with stage I-II primary gastric high-grade lymphoma (PGL) with a conservative strategy. Here we report a retrospective series of 21 patients with PGL treated with primary chemotherapy alone or followed by radiation ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909058457

    authors: Ferreri AJ,Cordio S,Ponzoni M,Villa E

    更新日期:1999-05-01 00:00:00

  • Case 30: hypereosinophilia.

    abstract::A young man presented with systemic symptoms and marked eosinophilia. Subsequently cyclical weight gain and edema contributed to a diagnosis. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600724878

    authors: Marks AJ,Abdalla SH,Cross NC,Bain BJ

    更新日期:2006-08-01 00:00:00

  • A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.

    abstract::Treatment options for patients who relapse following autologous transplantation for Hodgkin's lymphoma are limited. There are anecdotal reports of lengthy remissions following second autologous procedures, although treatment-related toxicity can be significant. We report a single centre experience of second autologous...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701216394

    authors: Thomson KJ,Peggs KS,Blundell E,Goldstone AH,Linch DC

    更新日期:2007-05-01 00:00:00

  • Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

    abstract::Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1361022

    authors: Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

    更新日期:2018-04-01 00:00:00

  • Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.

    abstract::Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1079313

    authors: Janikova A,Bortlicek Z,Campr V,Kopalova N,Benesova K,Hamouzova J,Belada D,Prochazka V,Pytlik R,Vokurka S,Pirnos J,Duras J,Mocikova H,Mayer J,Trneny M

    更新日期:2016-05-01 00:00:00

  • Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.

    abstract::131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study, 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4 x 10(6) U/m2 IFN a...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199309148513

    authors: Niederle N,Kloke O,Wandl UB,Becher R,Moritz T,Opalka B

    更新日期:1993-01-01 00:00:00

  • Comparison of bone marrow aspirates and biopsies in pediatric patients with ALL at days 7 and 14 of induction therapy.

    abstract::The percentage of blasts in the bone marrow aspirates at day 7 or 14 of induction therapy in pediatric ALL patients is an indicator of rapid early response and an independent prognostic factor for long term outcome. Discrepancies between the percentages of blasts in bone marrow aspirates compared to biopsies have been...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001625863

    authors: Countouriotis A,Landaw EM,Naeim F,Moore TB,Sakamoto KM

    更新日期:2004-04-01 00:00:00

  • Primary multifocal lymphoma of bone presenting as hypercalcemic crisis: report of a rare manifestation of extranodal lymphoma.

    abstract::Primary non-Hodgkin's lymphoma of bone is uncommon and usually manifests clinically as localized bone pain. Here we report a woman who presented with hypercalcemic crisis and extensive investigation revealed a primary multifocal lymphoma of bone. The course of the disease was very aggressive and despite intensive supp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909083398

    authors: Evron E,Goland S,Klepfish A,Malnick SD,Sokolowski N,Sthoeger ZM

    更新日期:1999-06-01 00:00:00

  • Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes.

    abstract::It has recently been postulated that the absence of a single tumor suppressor gene (TSG) allele can provide a selective advantage for an emerging tumor cell. We have characterized the precise extension of the deletion on der(9) in 20 chronic myeloid leukemia (CML) cases using FISH analysis with an appropriate set of B...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001623900

    authors: Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Liso A,Pannunzio A,Pastore D,Mestice A,Greco G,Liso V,Rocchi M

    更新日期:2004-04-01 00:00:00

  • Transition of polycythemia vera to chronic neutrophilic leukemia.

    abstract::Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909093744

    authors: Higuchi T,Oba R,Endo M,Harada H,Mori H,Niikura H,Omine M,Fujita K

    更新日期:1999-03-01 00:00:00

  • Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.

    abstract::The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.588761

    authors: Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

    更新日期:2011-10-01 00:00:00

  • P-Glycoprotein Expression in Drug-Resistant Chronic Lymphoproliferative Disorder.

    abstract::Peripheral blood lymphocytes from 60 patients with drug-resistant chronic lymphoproliferative disorders (LPD) were examined for expression of P-glycoprotein (P-gp) by direct immunofluorescence (IF) test using monoclonal antibody (MoAb) C219. Four of the 15 patients with prolymphocytic leukaemia (PLL), and both patient...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109067633

    authors: Majumdar G,Singh AK

    更新日期:1991-01-01 00:00:00

  • Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.

    abstract::This study was designed to evaluate the efficacy and toxicity of dose intensifying DHAP (dexamethasone, cytarabine and cisplatin) salvage chemotherapy by adding mitoxantrone with GM-GSF support in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). From March 1992 to January 1995, 22 patients with inter...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/10428199909169617

    authors: Haq R,Sawka CA,Franssen E,Berinstein NL

    更新日期:1999-11-01 00:00:00

  • IRF-3 gene polymorphisms are associated with the susceptibility to and the survival in chronic lymphocytic leukemia and could also serve as an auxiliary index.

    abstract::The objective of this article was to investigate the relationship between IRF-3 gene polymorphisms and the susceptibility and prognosis of CLL. Between January 2011 and August 2012, 108 CLL patients and 112 healthy were enrolled in the study. DHPLC and Shesis software were applied in our study. In rs7251, CG genotype ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1193858

    authors: Zhang ZX,Shen CF,Shou LH,Fang Q

    更新日期:2017-03-01 00:00:00

  • Comparison of the survivals between bone marrow transplantation and chemotherapy for acute leukemia in first remission--a Japanese single institution study.

    abstract::The outcome of sixty-four patients with acute leukemia in first remission who had been treated with either bone marrow transplantation (BMT) or conventional chemotherapy was retrospectively evaluated (a median follow-up of 37 months). Among them, 26 patients (age range; 14-42 years) received allogeneic BMT from HLA-id...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199209051015

    authors: Tamura S,Takemoto Y,Kanamaru A,Fujiwara H,Miyazaki E,Fujimori Y,Inoue N,Okamoto T,Kohsaki M,Kakishita E

    更新日期:1992-11-01 00:00:00